Clinical Trial Record

Return to Clinical Trials

Genetic Testing Decision Aid


2022-10-14


2025-10-31


2025-10-31


350

Study Overview

Genetic Testing Decision Aid

This is a randomized trial to evaluate the effectiveness of an electronic decision aid tool versus a traditional genetic counselor session for multi-gene panel testing for people with ovarian or pancreatic cancer

The research study procedures include: screening for eligibility and study questionnaires that would be performed in conjunction with either the genetic counselor visit or use of the electronic decision aid. The study questionnaires include: * Knowledge Survey * Shared Decision Making Process Survey * Decisional Conflict Scale The research study will last up to 2 weeks. It is expected that about 350 people will take part in this research study. The National Cancer Institute (NCI) is supporting this research study by providing funding for the research

  • Epithelial Ovarian Carcinoma
  • Pancreas Adenocarcinoma
  • BEHAVIORAL: Electronic Decision Aid
  • BEHAVIORAL: Pre-Test Genetic Counseling
  • 22-155
  • U01CA243695 (U.S. NIH Grant/Contract)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2022-07-15  

N/A  

2024-03-01  

2022-07-20  

N/A  

2024-03-04  

2022-07-22  

N/A  

2024-03  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Health Services Research


Allocation:
Randomized


Interventional Model:
Parallel


Masking:
None


Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Electronic decision aid arm

Receive decision aid followed by an appointment with their oncologist.

BEHAVIORAL: Electronic Decision Aid

  • Decision aid followed by an appointment with an oncologist. Will complete surveys/questionnaires
ACTIVE_COMPARATOR: Genetic counselor Arm

Receive pretest counseling with a genetic counselor.

BEHAVIORAL: Pre-Test Genetic Counseling

  • Receive pretest counseling with a genetic counselor. Will complete surveys/questionnaires
Primary Outcome MeasuresMeasure DescriptionTime Frame
Average change in knowledge survey scoreAverage change in score on a 10-question knowledge survey to assess basic information about genetics and genetic testing that was covered in their appointment. Scores on the scale range from 0-10. Higher values in the change in knowledge survey score suggest greater amount of knowledge gained in the genetics session.baseline (prior to participant completing either genetics sessions) to 1-week following session, approximately 2 weeks
Decisional Conflict ScoresThe decisional conflict score is a score ranging from 0-100 that is measured from a 10-question validated decisional conflict scale. The scale assesses participant's confidence in their decision with higher scores indicating higher decisional conflict.1 week after genetics session
Shared Decision Making Process ScoresThe shared decision making process score is a score on a scale of 1-4 based on responses on a validated 4-item shared-decision making scale. The scale assesses how well the decision aid/oncology provider, or the genetic counselor engaged in shared decision-making as perceived by the subject. Higher scores on this scale indicate more shared decision making.1 week after genetics session
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Average time between genetic testing recommendation and sample collectionDifference between the two study arms in the time it takes between participants being recommended for genetic testing and a sample being collected.Initial recorded recommendation/referral for genetic testing until the date of sample collection, assessed up to 6 months
Average Duration of Decision Making ProcessAmount of time patients spend learning and making a decision about genetic testing in both arms of the study.Approximately 30 minutes - 1 hour
Ratio of the number of participants who chose each of the three panels offeredRatios of participants who choose the small, intermediate, and broad testing panel in both arms of the study.At the conclusion of genetics session (day 1)
Percentage of participants choosing genetic testingPercentage of participants in each arm of the study who choose to get genetic testing after the educational interventionAt the conclusion of genetics session (day 1)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Daniel C. Chung, MD

Phone Number: (617) 726-8687

Email: Chung.daniel@mgh.harvard.edu

Study Contact Backup

Name: Danielle A Lynch, BS

Phone Number: (617) 726-1355

Email: dlynch22@mgh.harvard.edu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • 18 years or older
  • Being seen in clinic at Massachusetts General Hospital or Boston Medical Center
  • Diagnosed with malignant epithelial ovarian carcinoma or malignant pancreatic adenocarcinoma.

  • Exclusion Criteria :

  • Unable or unwilling to provide informed consent, undergo randomization, or complete the surveys associated with the study
  • Previous germline genetic testing
  • History of hereditary pancreatitis
  • Members of the following vulnerable populations: adults unable to consent, individuals who are not yet adults

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

  • National Cancer Institute (NCI)

  • PRINCIPAL_INVESTIGATOR: Daniel C. Chung, MD, Massachusetts General Hospital

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available